Señales en vivo de IMU.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:10):

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia...

Stats
Volumen de hoy	17.07M
Volumen promedio	15.87M
Capitalización de mercado	578.26M
EPS	$0 ( 2024-03-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.90
ATR14	$0 (0.00%)

Volumen Correlación

Largo: -0.12 (neutral)

Corto: -0.69 (moderate negative)

Signal:(45.931) Neutral

Imugene Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Imugene Ltd Correlación - Moneda/Commodity

0.00
( neutral )

Imugene Ltd Finanzas

Annual	2023
Ingresos:	$11.78M
Beneficio Bruto:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2023
Ingresos:	$11.78M
Beneficio Bruto:	$9.57M (81.29 %)
EPS:	$-0.00600

FY	2022
Ingresos:	$12.97M
Beneficio Bruto:	$10.56M (81.44 %)
EPS:	$-0.00670

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.00453

Financial Reports:

No articles found.

Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.